{"id":3742,"date":"2025-06-16T10:00:58","date_gmt":"2025-06-16T08:00:58","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=3742"},"modified":"2025-06-09T10:32:43","modified_gmt":"2025-06-09T08:32:43","slug":"durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/","title":{"rendered":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low tissue or blood tumor mutational burden&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]<a href=\"https:\/\/www.esmoopen.com\/article\/S2059-7029(25)00927-5\/fulltext\" target=\"_blank\" rel=\"noopener\">An updated analysis from the phase 3 POSEIDON study recently published on ESMO Open<\/a>\u00a0shows that a first line treatment with tremelimumab plus durvalumab and chemotherapy consistently improved clinical outcomes in patients with metastatic non-small-cell lung cancer (NSCLC) in both blood tumor mutational burden high or low subgroups and in both high and low tissue tumor mutational burden subgroups.<\/p>\n<p>In the POSEIDON study, after a median follow-up of more than 5 years, first line tremelimumab plus durvalumab and chemotherapy showed durable long-term overall survival benefit versus chemotherapy alone in metastatic NSCLC. Tumor mutational burden (TMB), defined as the number of somatic mutations present in DNA derived from blood (bTMB) or tumor tissue (tTMB), has potential as a predictive biomarker for immunotherapy treatment benefit, in particular for combined anti-PD-L1 plus anti-CTLA-4 therapy independent of PD-L1 expression. Thus, authors analyzed outcomes of POSEIDON patient subgroups defined by a range of bTMB and tTMB values. Results showed an overall survival and progression free survival benefit for tremelimumab plus durvalumab and chemotherapy in both bTMB-high and bTMB-low subgroups and both tTMB-high and tTMB-low subgroups at all cut-offs, with a magnitude of benefit greater in TMB-high compared with TMB-low subgroups. As authors conclude, \u00abIn patients with metastatic NSCLC, first-line treatment with a limited course of tremelimumab plus durvalumab (until progression) and four cycles of chemotherapy consistently improved clinical outcomes versus chemotherapy alone. Benefit appeared greater in the TMB-high compared with TMB-low subgroups; the addition of anti-CTLA-4 to anti-PD-L1 and chemotherapy seemed to increase the magnitude of this difference. However, in view of the limited benefit, TMB testing is not warranted in this setting\u00bb.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;2843&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low tissue or blood tumor mutational<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":2844,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-3742","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low tissue or blood tumor mutational burden\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low tissue or blood tumor mutational burden\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T08:00:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_30135963_XL.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer\",\"datePublished\":\"2025-06-16T08:00:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Depositphotos_30135963_XL.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/\",\"name\":\"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Depositphotos_30135963_XL.jpg\",\"datePublished\":\"2025-06-16T08:00:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low tissue or blood tumor mutational burden\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Depositphotos_30135963_XL.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Depositphotos_30135963_XL.jpg\",\"width\":2500,\"height\":1500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer - Fondazione Gianni Bonadonna","description":"First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low tissue or blood tumor mutational burden","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer - Fondazione Gianni Bonadonna","og_description":"First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low tissue or blood tumor mutational burden","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2025-06-16T08:00:58+00:00","og_image":[{"width":2500,"height":1500,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_30135963_XL.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer","datePublished":"2025-06-16T08:00:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/"},"wordCount":357,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_30135963_XL.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/","name":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_30135963_XL.jpg","datePublished":"2025-06-16T08:00:58+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low tissue or blood tumor mutational burden","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_30135963_XL.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_30135963_XL.jpg","width":2500,"height":1500},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=3742"}],"version-history":[{"count":2,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3742\/revisions"}],"predecessor-version":[{"id":3831,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3742\/revisions\/3831"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/2844"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=3742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=3742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=3742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}